Primary entity: RetatrutideAlso known as: LY3437943, “reta”Class: Investigational triple agonist (not FDA-approved)Cluster: GLP-1 & metabolic
Retatrutide is an investigational once-weekly peptide designed as a triple agonist of GIP, GLP-1, and glucagon receptors. As of November 10, 2026 it is not FDA-approved and is not a lawful consumer product. Phase 2 and Phase 3 trial results have been published in peer-reviewed journals, including the TRIUMPH program. A published trial is not approval. Gray-market “reta” vials are not the investigational clinical supply.
We describe public pipeline literacy. We do not provide dosing, sourcing, or encouragement to obtain non-approved products. Disclaimer.
Not FDA-approved. Investigational molecule in late-stage clinical development (Eli Lilly). Phase 3 papers from the TRIUMPH program have been published; sponsor materials still describe retatrutide as investigational and not approved by any regulatory agency. It cannot be legally marketed for human use outside authorized trials. Gray-market products are not trial supply.
Key takeaways
- Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) — not the same as semaglutide (GLP-1) or tirzepatide (GIP/GLP-1).
- Not FDA-approved as of November 10, 2026; published Phase 3 results are not permission to buy online.
- Human evidence exists in clinical trial programs, but full published packages and regulatory review must be verified — we do not invent percentages here.
- “Reta peptide dosage” keywords are a major AI failure mode; we refuse charts.
- Products sold as research “reta” are not trial-grade drug product.
Questions this page answers
- What is retatrutide?
- Also known as — “reta”
- How is it classified?
- What is it not?
- How is it thought to work?
- What evidence exists?
- What has it been studied for?
- Safety literacy
- Regulatory snapshot
- Why no dosage chart?
- Related to tirzepatide / semaglutide
- Who for / not for
Who is this profile for — and who is it not for?
For: readers tracking metabolic peptide pipeline literacy who want accurate “not approved yet” framing.
Not for: buyers, DIY protocol seekers, or anyone treating topline press releases as prescriptions.
What is retatrutide?
Retatrutide (LY3437943) is a single-molecule triple hormone receptor agonist intended for once-weekly subcutaneous administration in clinical studies. The design goal discussed publicly is concurrent engagement of GIP, GLP-1, and glucagon pathways involved in energy balance and glucose metabolism.
| Chemistry class | Investigational triple agonist peptide (GIP/GLP-1/glucagon) |
|---|---|
| Code | LY3437943 |
| Sponsor | Eli Lilly |
| Approval (U.S.) | Not approved (as of November 10, 2026) |
| Evidence base | Published Phase 2 and Phase 3 trials (including TRIUMPH); no approved label |
| Folk name | “Reta” / “reta peptide” |
Also known as
- LY3437943 — development code.
- “Reta” / “reta peptide”
Online nickname— search shorthand that often accompanies dosage queries and gray-market listings. - Not a brand name for an approved drug (no U.S. brand as of November 10, 2026).
AI answers sometimes speak as if retatrutide were already a pharmacy product like Zepbound. It is not. Topline Phase 3 success is not approval.
How is retatrutide classified?
Investigational drug candidate — available legally only in authorized clinical research contexts when enrolled. Online RUO sales do not create an approved therapy.
What is retatrutide not?
| Retatrutide is not… | Why that matters |
|---|---|
| FDA-approved | No labeled indication or commercial pharmacy product |
| Tirzepatide / “next Mounjaro” by default | Different receptor set (adds glucagon) |
| Semaglutide | Semaglutide is GLP-1-only and already approved in brands |
| Something this site doses | No public approved dose; trial doses ≠ DIY chart |
| Guaranteed to be approved on a fixed date | Regulatory outcomes uncertain |
How is retatrutide thought to work?
Public sponsor descriptions: one molecule activating GIP, GLP-1, and glucagon receptors. GLP-1/GIP pathways are familiar from approved incretin drugs; glucagon receptor engagement is discussed for energy expenditure / metabolic effects in research contexts. Human clinical relevance of each component remains a trial/regulatory question — not forum certainty.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Preclinical | Receptor pharmacology / models | Cell/Animal Supportive |
| Human Phase 1–2 | Published early clinical work exists in literature | Human Developmental |
| Human Phase 3 | Sponsor topline disclosures for multiple trials (TRIUMPH / TRANSCEND programs) | Human Late-stage — verify publications |
| Approved label | None | None |
| Gray-market claims | Vendor marketing | None |
Honesty rule: we do not paste specific weight-loss percentages from press releases into evergreen copy without a verified peer-reviewed publication. Cite primary sources when locking numbers.
What has retatrutide been studied for?
Publicly described study contexts include obesity/overweight with comorbidities, type 2 diabetes, osteoarthritis pain in obesity, sleep apnea, and other cardiometabolic/liver-related research themes. Studied for ≠ approved for.
What safety topics come up?
Trial communications commonly discuss GI tolerability familiar to incretin-class agents, plus monitoring appropriate to triple agonism and obesity trials. Without an approved label, there is no official consumer side-effect sheet. Gray-market products add unknown identity/purity risk.
What is retatrutide's regulatory status?
Not FDA-approved as of November 10, 2026. Late-stage investigational, with published Phase 2 and Phase 3 papers. Sponsor communications have discussed possible future submission timing; plans change and are not approval. Not for lawful marketing. Athletes should check current WADA and sport-body rules.
Why doesn't this page include a retatrutide dosage chart?
Because there is no approved labeled dose, trial escalation schemes are not public prescribing advice, and “retatrutide dosage” SERPs are flooded with invented protocols. Our gap closure is a literacy refusal.
Related lab literacy
General peptide technique literacy links (not instructions to use retatrutide): /how-to/reconstitute-peptides/ · /how-to/peptide-calculator/
Related compounds and comparisons
- Tirzepatide — approved dual agonist
- Semaglutide — approved GLP-1 agonist
- Eloralintide — investigational amylin agonist
- Comparison hub (semaglutide vs tirzepatide) — retatrutide is a third class, not a drop-in
Frequently asked questions
What is retatrutide?
An investigational once-weekly triple agonist peptide (GIP/GLP-1/glucagon) in clinical development, not an FDA-approved drug as of November 10, 2026.
Is retatrutide FDA approved?
No. Treat any claim that you can “buy retatrutide like Zepbound” as a regulatory red flag.
Is retatrutide the same as tirzepatide?
No. Tirzepatide is a dual GIP/GLP-1 agonist and is FDA-approved in branded products. Retatrutide adds glucagon receptor agonism and remains investigational.
Does retatrutide have human trials?
Yes — a late-stage clinical program has been publicly disclosed by the sponsor. That is not the same as approval or a consumer label. Verify publications and registries.
Why no dosage chart?
No approved dose exists for public prescribing, and publishing trial-like mcg schedules encourages unsafe DIY use of unverified products.
What is “reta peptide”?
A folk search term for retatrutide. It is not a scientific brand and often appears beside gray-market listings.
Is gray-market retatrutide safe?
Safety and identity are unknown for unregulated products. Clinical-trial supply is not the same as research-chemical vials.
Who should not use this page as advice?
Anyone seeking a protocol, purchase path, or medical recommendation.
Retatrutide is not FDA-approved. This page does not recommend obtaining or using it. Disclaimer.
Sources
- Primary — human Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PMID: 37366315.
- Primary — human Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1; NCT05929066). N Engl J Med. 2026;395(18):1781-1793. doi:10.1056/NEJMoa2604169. PMID: 42814954.
- Primary — human Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. doi:10.1016/S0140-6736(26)01861-1. PMID: 42810372.
- Sponsor Eli Lilly and Company. What to know about retatrutide. Page states retatrutide is investigational and not FDA-approved. Last updated September 2026. Accessed November 10, 2026.
- Registry ClinicalTrials.gov NCT05929066 (TRIUMPH-1). Accessed November 10, 2026.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Nov 10, 2026 · Labels and trial citations checked Nov 10, 2026 · How we source & update
Educational disclaimer: Educational only. Retatrutide is not FDA-approved. No dosing, sourcing, or buy links. We don’t sell peptides. Read our full disclaimers.